The JUN Knockout A2780 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population targeting the human JUN gene, which encodes the transcription factor c-Jun. Generated through CRISPR/Cas9-mediated gene disruption in the A2780 ovarian carcinoma cell line, this product provides a genetically heterogeneous loss-of-function model suitable for studying the functional consequences of JUN ablation in an epithelial ovarian cancer background. Unlike clonal cell lines, this polyclonal population retains a distribution of edited alleles across the cell pool, enabling robust assessment of JUN-dependent phenotypes without the confounding effects of single-cell clonal selection. The knockout disrupts the endogenous AP-1 transcriptional network, offering a powerful tool for investigating c-Jun biology in cancer signaling, stress responses, and drug resistance.
The A2780 cell line is an adherent epithelial line originally established from an untreated patient with ovarian adenocarcinoma. As a widely used model for ovarian carcinoma research, A2780 cells faithfully recapitulate key aspects of ovarian tumor biology, including sensitivity to platinum-based chemotherapeutics such as cisplatin. Their genetic background and signaling dependencies make them particularly relevant for dissecting the molecular mechanisms underlying tumor cell proliferation, invasion, and therapeutic resistance. The A2780 host cell line thus provides a clinically pertinent context for interrogating JUN function.
c-Jun serves as a core component of the activator protein-1 (AP-1) transcription factor complex, which plays a central role in regulating gene expression programs governing cell proliferation, differentiation, apoptosis, and stress responses. Activation of c-Jun occurs primarily through phosphorylation by upstream kinases, including JNK (MAPK8/9), ERK (MAPK1/3), and p38 MAPK, in response to growth factors such as EGF and PDGF, as well as cellular stressors like UV irradiation and osmotic shock. Upon phosphorylation, c-Jun dimerizes with other AP-1 family members??including c-Fos, FosB, Fra-1, Fra-2, JunB, JunD, and ATF2??to form transcriptionally active complexes that bind AP-1 response elements in target gene promoters. Through these interactions, c-Jun regulates a diverse array of downstream effectors, including CCND1 (cyclin D1) for cell cycle progression, TP53 and BCL2 for apoptosis control, MMP1 and MMP9 for extracellular matrix remodeling, VEGFA for angiogenesis, and IL2 for immune modulation. Additionally, c-Jun cooperates with coactivators like CBP/p300 and integrates signals from the Wnt and TGF-beta pathways via interactions with SMAD3 and NFAT, situating it at a signaling nexus critical for oncogenic processes.
In the A2780 ovarian cancer model, JUN knockout disrupts AP-1?Cdriven transcriptional programs that are frequently hyperactivated in ovarian carcinoma. The MAPK/JNK signaling cascades converge on c-Jun to promote tumor cell proliferation, survival, and invasive behavior. By ablating JUN, this polyclonal knockout model impairs the expression of key targets such as CCND1 and MMPs, which are implicated in cell cycle progression and metastatic dissemination. Consequently, these cells enable dissection of JUN??s specific role in mediating drug resistance mechanisms, as c-Jun has been linked to cisplatin sensitivity and adaptive stress responses in ovarian tumors. The polyclonal nature of the knockout population ensures that observed phenotypes reflect the average effect of JUN loss across a mixed genetic landscape, avoiding artifacts from individual clonal isolates.
This product is suited for a broad range of research applications, including the study of AP-1 transcriptional activity in ovarian cancer, investigation of JUN-dependent signaling in tumorigenesis, and functional complementation assays. Researchers can employ techniques such as Western blotting to assess JUN and phospho-c-Jun levels, RT-qPCR to measure AP-1 target gene expression, and AP-1 luciferase reporter assays to quantify transcriptional output. Phenotypic assays, including proliferation, transwell migration/invasion, and drug sensitivity screening (e.g., with cisplatin), can further define the functional consequences of JUN knockout. Additionally, RNA-seq transcriptomic profiling can reveal global gene expression changes linked to JUN loss. For inquiries or to obtain this product, please contact Ascent Research.
